Sarepta posts first Phase 4 ENDURE real-world safety data for Elevidys in Duchenne patients at NMSG 2026
SRPT•Sarepta Therapeutics said it will present interim Phase 4 ENDURE data on real-world safety for Elevidys in Duchenne patients at the Neuromuscular Study Group meeting on Sept. 25-27, 2026.
1. Data presentations planned
The interim ENDURE results will cover real-world safety in Duchenne patients receiving Elevidys in routine clinical care. Poster analyses will also examine how treatment timing relates to outcomes, while separate early-stage updates will address safety and drug exposure for SRP-1003 in DM1 and SRP-1001 in FSHD1.
